AstraZeneca (LON:AZN) has been given a GBX 5,500 ($77.74) price target by research analysts at JPMorgan Chase in a research note issued to investors on Friday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase’s price objective suggests a potential upside of 9.39% from the company’s previous close.
A number of other research analysts also recently commented on the company. Shore Capital reissued a “hold” rating on shares of AstraZeneca in a report on Wednesday. Deutsche Bank reissued a “buy” rating on shares of AstraZeneca in a report on Monday. Morgan Stanley reissued an “equal weight” rating and issued a GBX 5,250 ($74.20) price target on shares of AstraZeneca in a report on Tuesday, March 27th. BNP Paribas reissued an “outperform” rating and issued a GBX 5,600 ($79.15) price target on shares of AstraZeneca in a report on Thursday, March 22nd. Finally, Credit Suisse Group reissued an “outperform” rating and issued a GBX 5,800 ($81.98) price target on shares of AstraZeneca in a report on Tuesday, March 20th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. AstraZeneca has a consensus rating of “Hold” and a consensus target price of GBX 5,224.70 ($73.85).
Shares of AZN opened at GBX 5,028 ($71.07) on Friday. AstraZeneca has a one year low of GBX 4,260 ($60.21) and a one year high of GBX 5,520 ($78.02).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.